Envudeucitinib
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Envudeucitinib
- Molecular weight
- 426.51
- Structure (SMILES)
These details could not be displayed.
- cyclopropanecarboxamide n 4 2 methoxy 3 1 methyl d3 1h 1 2 4 triazol 3 yl phenyl amino 5 1 oxopropyl 3 3 3 d3 2 pyridinyl
- Cyclopropanecarboxamide, N-[4-[[2-methoxy-3-[1-(methyl-d3)-1H-1,2,4-triazol-3-yl]phenyl]amino]-5-(1-oxopropyl-3,3,3-d3)-2-pyridinyl]-
- envudeucitinib
- Envudeucitinib
- envudeucitinib [INN]
- ENVUDEUCITINIB [USAN]
- envudeucitinib inn
- envudeucitinib usan
- esk 001
- ESK 001 [WHO-DD]
- esk 001 who dd
- ESK-001
- ftp 637
- FTP-637
- CAS registry numbers
- 2417135-66-9
- ChEMBL ID
- CHEMBL5415395
- InChIKey
- FKCATCQHVCOBCX-WFGJKAKNSA-N
- PubChem compound IDs
- 158715582
- FDA ingredient codes (UNII)
- KD2MDJ4GAB
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- envudeucitinib
- Type
- Synthetic organic
- Drug name stem
- -tinib
Investigated indications
- Condition
- Inflammation
- Highest recorded phase
- 2
- Condition identifier
- MP:0001845
- Subject identifier
- D007249
- Condition identifier
- EFO_1001494
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0006806
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0006918
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007915
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0017255
- Highest recorded phase
- 2
- Condition identifier
- MP_0001845
- Hydrogen bond acceptors
- 8
- Hydrogen bond donors
- 2
- Polar surface area
- 111.03
- Calculated partition coefficient (ALogP)
- 3.57
- Calculated partition coefficient (XLogP)
- 2.8
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 8
- Heavy atoms
- 31
- Molecular formula
- C22H24N6O3
- Monoisotopic mass
- 426.22864912
- Natural product
- No
- Recorded assays
- 6
- Active assays
- 1
Active assay types
- Confirmatory
Related records
Trials (10)
- A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001
- A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis
- A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis
- An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage
- An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function
- An Investigational Study to Evaluate the Cardiac Safety Assessment (TQTc Study) of ESK-001
- Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis
- Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus
- POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIU
- Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants